Results 131 to 140 of about 35,993 (244)

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint

Cardiology Journal
The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A. Gorog, Paul A. Gurbel, Tomasz Hajdukiewicz, Bartosz Hudzik, Stefan James, Young-Hoon Jeong, Adam Kern, Wacław Kochman, Aldona Kubica, Wiktor Kuliczkowski, Przemysław Magielski, Piotr Niezgoda, Małgorzata Ostrowska, Paolo Raggi, Uzeyir Rahimov, Grzegorz Skonieczny, Jolanta M. Siller-Matula, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Julia Umińska, Eliano Pio Navarese   +31 more
doaj   +1 more source

Comparison of P2Y12 inhibitors vs. aspirin monotherapy following dual antiplatelet therapy in patients after percutaneous coronary intervention: a systematic review and meta-analysis

Archives of Medical Science: Atherosclerotic Diseases
Introduction P2Y12 inhibitor monotherapy has emerged as a potential alternative to aspirin following dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI), but the optimal choice remains uncertain.
Muhammad Hazqeel Kazmi, Taha Kassim Dohadwala, Syed Mohammad Haleem, Umabalan Thirupathy, Piyush Sajnani, Pena Campos Indira Camila, Mennatalla Ayyad, Brandon Xian Ch’ng, Muhammad Muneeb Arshad, Ibrahim Ali Nasser, Ahmad Mesmar, Muhammad Nadeem Khawaja, Amer Mohammad Amin Al-Zou’bi, Salman Chatha, Osama Tariq, Eeshal Zulfiqar, Mushood Ahmed, Raheel Ahmed   +17 more
doaj   +1 more source

Biallelic mutations in NRROS cause an early onset lethal microgliopathy. [PDF]

, 2020
Armishaw, J, Barrington, J, Bridges, LR, Clarke, A, Crow, YJ, Eaton, J, Hobbs, V, Jeffrey, IJM, Livingston, JH, Mansour, S, McColl, BW, Nolan, M, Patir, A, Rice, GI, Rodero, MP, Seabra, L, Smith, C, Uggenti, C   +17 more
core   +2 more sources

P2Y12 and P2Y12-related genetic analysis

Japanese Journal of Thrombosis and Hemostasis, 2012
openaire   +2 more sources

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease

JCI Insight
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD).
Deirdre Nolfi-Donegan, Gowtham K. Annarapu, Claudette St. Croix, Michael Calderon, Cheryl A. Hillery, Sruti Shiva   +5 more
doaj   +1 more source

Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. [PDF]

PLoS Med
Navarese EP, Gurbel P, Tantry U, Talanas G, Grzelakowska K, Umińska J, Jeong YH, Bliden K, Khan SU, Kubica J, Henry TD, Farkouh ME, Kereiakes DJ.   +12 more
europepmc   +1 more source

Dual antiplatelet therapy in acute ischemic stroke: Does diabetes mellitus define a target population? [PDF]

Neurotherapeutics
Nedelcu S.
europepmc   +1 more source

Neurotransmitter signaling in white matter [PDF]

, 2014
Butt, Arthur M., Fern, Robert F., Matute, Carlos   +2 more
core   +1 more source

Single-Site Experience in the ONSET-OFFSET Study Demonstrates Pharmacodynamic and Pharmacokinetic Advantages of Ticagrelor over Clopidogrel in Patients with Chronic Coronary Syndromes. [PDF]

J Cardiovasc Dev Dis
Judge HM, Parker WAE, Storey RF.
europepmc   +1 more source

The DRY motif at work: the P2Y12 receptor case [PDF]

Journal of Thrombosis and Haemostasis, 2014
G. Rovati, V. Capra
openaire   +2 more sources